Login to Your Account

Oncolytics' First Phase II Data: Another Winner in Melanoma?

By Randy Osborne
Staff Writer

Wednesday, May 22, 2013
Oncolytics Biotech Inc. followed up March's promising data from a Phase II trial testing Reolysin in squamous cell lung cancer with results from a Phase II study in metastatic melanoma, where the reovirus variant for Ras-mutant cancers, combined with carboplatin and paclitaxel, met its primary endpoint in the first stage.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription